HLA
GNCA

Hamilton Lane Advisors’s Genocea Biosciences, Inc. GNCA Stock Holding History

Hamilton Lane Advisors’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,670
Closed -$70K – 68
2017
Q2 		$70K Sell
1,670
-9
-0.5% -$433 0.04% 50
2017
Q1 		$82K Buy
+1,679
New +$65.6K 0.04% 58

Other funds holding GNCA

PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AA
AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return

Hamilton Lane Advisors's GNCA Position: Q3 2017 in Review

Hamilton Lane Advisors sold out of Genocea Biosciences, Inc. (GNCA) in Q3 2017, closing a stake of 1,670 shares — an estimated $70K sold.

Hamilton Lane Advisors first reported a position in GNCA in Q1 2017 and held it in 2 quarters. The position peaked at $82K in Q1 2017. 62 funds tracked by Wall St. Rank hold GNCA as of Q3 2017.

  • Hamilton Lane Advisors reported no remaining Genocea Biosciences, Inc. position as of Q3 2017 after selling out during the quarter.
  • Hamilton Lane Advisors sold 1,670 Genocea Biosciences, Inc. shares in Q3 2017, an estimated $70K.
  • Hamilton Lane Advisors first reported a position in Genocea Biosciences, Inc. in Q1 2017 and held it in 2 quarters.
  • Hamilton Lane Advisors's Genocea Biosciences, Inc. position peaked at $82K in Q1 2017.
  • 62 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q3 2017.

Based on Hamilton Lane Advisors's 13F filing for Q3 2017, filed 16 Oct 2017.